Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?

Publication | Closed Access

DOI

Citations

References

2010

Year

Rao N. V. S. Mamidi, STEVE WENG, Susan Stellar, Charles Wang, Ning Yu, Tony Jun Huang, Alfred Tonelli, Michael F. Kelley, Anthony Angiuoli, Man‐Cheong Fung

Cancer Chemotherapy and Pharmacology

Pharmaceutical SciencePreclinical Drug EvaluationBioequivalenceMedicineLiposomal Doxorubicin ProductsTherapeutic EquivalencePharmacotherapyDrug DevelopmentPharmacologyPharmacokineticsLiposomal Doxorubicin Formulations